Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis
Abstract:SETTING: Mycobacteria Supranational Reference Laboratory.
OBJECTIVE: To evaluate the Mycobacteria Growth Indicator Tube (MGIT) method for drug susceptibility testing of Mycobacterium tuberculosis.
DESIGN: One hundred and one clinical strains of M. tuberculosis were evaluated for their susceptibilities to isoniazid (INH), rifampicin (RIF), ethambutol (EMB) and streptomycin (SM) by MGIT and by the proportion method on Löwenstein-Jensen (L-J) medium. The concentrations of drugs in MGIT were: 0.1, 1.0, 3.5 and 0.8 μg/ml for INH, RIF, EMB and SM, respectively.
RESULTS: The results for individual drugs showed a good correlation: the specificity was 100% for INH, RIF and EMB and 92% for SM; the sensitivity was 100%, 94.6%, 96.1% and 89.7% for INH, RIF, EMB and SM, respectively, and the accuracy values 1.0, 0.98, 0.99 and 0.91.
CONCLUSION: The MGIT system appears to be a reliable and simple non-radiometric method for the drug susceptibility testing of M. tuberculosis.
Document Type: Regular Paper
Affiliations: Mycobacteriology Unit, Department of Microbiology, Institute of Tropical Medicine Prince Leopold, Antwerp, Belgium
Publication date: 1999-04-01
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites